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Background: Economic costs related to treatment of multiple sclerosis (MS) must be justified by health state,
quality of life (QOL) and social participation improvement. This study aims to describe correlations between social
participation, economic costs, utility and MS-specific QOL in a sample of patients with MS (pwMS).
Methods: We interviewed 42 pwMS receiving natalizumab and collected clinical data, direct medical costs,
productivity loss, utility (EQ5D-VAS), MS-specific QOL (SEP-59), social participation with the Impact on Participation
and Autonomy questionnaire (IPA). We performed descriptive and correlation analyses.
Results: 41 pwMS, with a mean Expanded Disability Status Scale (EDSS) score of 4.0, completed questionnaires.
Mean annual global cost per patient was 68448 +/−33374 Euros and increased with EDSS (r = 0.644), utility
(r = −0.456) and IPA (r = 0.519-0.671) worsening. Mean utility was 0.52 +/− 0.28. Correlations between IPA and QOL
(EQ5D-VAS or SEP-59) were observed (r = −0.53 to −0.78). Association between QOL and EDSS was smaller
(EQ5D-VAS) or absent. Productivity losses were poorly correlated to EDSS (r = 0.375).
Conclusion: Moderate to strong correlations of social participation with clinical status (EDSS), QOL, utility and
economic costs encourage exploring better these links in larger cohorts. The stronger correlation between social
participation and QOL than between EDSS and QOL needs to be confirmed.
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Multiple sclerosis (MS) is a chronic inflammatory, de-
myelinating and neurodegenerative disease of the central
nervous system causing various neurological symptoms,
including motor, sensory, visual or cognitive troubles.
MS primarily strikes adults between 18 and 45 years and
has several forms of presentation [1]. 85% of patients
have relapsing-remitting MS (RR-MS) with periods of
defined relapse (with either fully recovery or residual
deficit after recovery) and periods characterized by a lack
of disease progression. Secondary progressive MS is an
initial relapsing-remitting course followed by progression* Correspondence: kwiatkowski.arnaud@ghicl.net
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article, unless otherwise stated.with or without occasional relapses (50% of RR-MS). In
about 15% of cases, primary progressive MS is a gradual,
nearly continuously worsening baseline with no distinct
relapse. Consequences of MS progression can be clinically
described with different scales or tools, but Expanded Dis-
ability Status Scale (EDSS) remains the most used outcome
in worldwide neurological community, even if numerous
shortcomings have been discussed [2]. Progressively, pa-
tients’ physical activities, ability to generate income [3] and
social participation [4] can be restricted. From the begin-
ning of the disease, MS significantly alters quality of life
(QOL) [5,6].
For over 15 years, clinical trials of various subcutane-
ously or intramuscularly immunomodulatory drugs have
demonstrated a modest reduction in relapse rate and lim-
ited effects on disability progression, with a well-known
long-term safety but a poor daily tolerability [1]. Recently,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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mod [8,9] showed greater effects on relapse rate and con-
vincingly on disease progression. However serious adverse
events and long-term safety remain a concern with such
drugs and require closed monitoring survey.
Treatment prices are an important vector of cost in
MS, essentially in initial phases of the disease [10] and
cost-effectiveness of all these drugs is questionable [11].
Economic evaluation is playing an increasing role in polit-
ical decisions for resources allocation and health policies.
In the current economic context with limited resources,
national or international institutions need up-to-date
economic burden studies and recommend assessment
of patient-reported outcomes (PRO) as utilities in clinical
trials [12,13]. Utility is most often assessed by preference-
based systems and through generic QOL measurement
tools, like EuroQol (EQ5D-VAS), Short Form Health Sur-
vey (SF-6D) or Health Utilities Index III (HUI-III). Most
studies in MS field have used EQ5D-VAS, in which
explored dimensions have important link to mobility
capacities [14]. However, several important domains of
impairments or limitations, as cognition, vision and others,
are poorly taken in count by these tools. Specific QOL
scales are available for patients with MS, but these do not
allow measuring utilities. Patient’s working capacity is well
evaluated with loss of production in global burden studies,
but others social disadvantages are only approached with
utility scales.
Our hypothesis is that disability in MS and particularly
social participation impairment should be better corre-
lated with utility, MS-specific QOL and economic costs
rather than health state described by an impairment scale
as EDSS. If it was verified, this relationship could lead to
an interesting tool for evaluation of health policy. Indeed,
a health-promoting action that could correct function-
ing or social participation deficits could be economically
recovered.
Our primary objective was to describe consequences
for patients treated by natalizumab in term of disabilities
and economic burden due to MS. In this study, disabil-
ities covered impairments, activity limitations and social
disadvantages, using EDSS and a measurement of auton-
omy and social participation. Secondary, we examined
correlations between usual tools, as EDSS, MS-specific
or generic QOL scales, and the “impact on participation
and autonomy questionnaire” (IPA).
Methods
Study participants
Researchers recruited consecutively a sample of patients
with MS who have monthly infusion of natalizumab, at
the Neurology Department, St Vincent de Paul Hospital,
Lille, France. Inclusion criteria were a diagnosis of MS
[15], an on-going treatment with natalizumab and to beat least 18 years old. Exclusion criteria were inability to
read/understand French, or unwillingness to participate.
Table 1 provides a summary of participants’ demographic
and medical information. This preliminary study was a
part of a larger study that was approved by the local ethic
committee named “Comité de Protection des Personnes
Nord Ouest IV” (number SC 11/02). A written informed
consent was obtained from patients who agreed to partici-
pate. Due to non-randomised inclusion of participants in
a unique centre and to limited time available to this first
study, the investigators chose to include only a representa-




The Impact on Participation and Autonomy Questionnaire
(IPA) assess the perceived personal impact of chronic dis-
ability on participation and autonomy. Effectively, World
Health Organisation’s International Classification of Func-
tioning, Disability and Health (ICF) was developed in 2001,
inspired by theorical researches in the forty last years, such
as Amartya Sen’s theory who define notions of functioning
and capabilities. In this context, the conceptual framework
of social participation has been defined as “the involvement
of an individual in life situations in relation to health con-
ditions, body function and structures, activities and con-
textual factors”. The IPA was developed and validated by
Cardol and colleagues in the Netherlands [16]. The IPA
was translated into English and validated for using by
patients which have disabilities due to MS, rheumatoid
arthritis and spinal cord injury [17,18]. A French version
was equally validated by Canadian researchers for eld-
erly people [19]. The IPA contains 32 items which load
onto five domains termed: autonomy indoors; family
role; autonomy outdoors; social life and relationships;
work and education. Scores for each domain range from
0 (“very good”) to 4 (“very poor”); lower scores indicate
better social participation and autonomy. In the validation
study of IPA questionnaire from UK, the control group
participants with mild or no disability had median
scores near from 0 (0 to 0.2) in all five domains from IPA.
Patients with MS experienced median scores between 0.67
to 2.2 [18].
Quality of life
Generic QOL questionnaire and utility
The EQ5D-VAS is a generic preference-based measure
of health-related QOL that consists of two parts. The
first part includes five domains (each divided in 3 levels:
no problem, some problems and extreme problems),
which are termed: mobility, capacity for self-care, conduct
of usual activities, pain/discomfort and anxiety/depression.
It permits to define 243 health states, which are valued in
Table 1 Demographics, utility, MS-specific QOL, IPA scores and economic costs in entire survey sample and 3 groups
separated by EDSS values
Survey sample EDSS
0-3.5 4.0-5.5 ≥6.0
No 41 17 17 7
Age (year) 42.8 (9.5)* 37.9 (9.7) § 45.5 (5.4) § 48.3 (12.2)
Sex-ratio M/W 7/34 3/14 2/15 2/5
Education level (year) 12.0 (3.3) 12.1 (3.4) 12.3 (3.4) 10.9 (3.1)
Disease duration (year) 11.7 (7.4)* 8.5 (5.3) § 11.1 (4.8) ¶ 20.9 (10) § ¶
EDSS 4.0 (1.6)* 2.5 (0.8) § 4.7 (0.6) § 6.2 (0.4) §
No of currently employed patients 24 14 10 0
Full time employment (%) 39% 53% 15% 0%
EQ5D-VAS score 0.52 (0.28)* 0.65 (0.31) § 0.44 (0.23) § 0.42 (0.24)
MSQOL-P 51.1 (19.1) 59.5 (21.4) 44.1 (17.0) 47.9 (10.1)
MSQOL-M 55.1 (24) 60.2 (23.2) 51.8 (23.8) 45.0 (14.3)
IPA
Autonomy indoors 0.91 (0.82)* 0.54 (0.57) § 1.17 (0.83) § 1.34 (1.14)
Family role 1.7 (0.8)* 1.21 (0.67) § 2.14 (0.68) § 1.91 (0.75)
Autonomy outdoors 1.89 (1.08)* 1.19 (0.88) § ¶ 2.49 (0.89) § 2.36 (0.96) ¶
Social life 1.1 (0.65)* 0.87 (0.69) § 1.14 (0.54) 1.71 (0.5) §
Work and education 2.54 (1.32)* 1.74 (1.18) § 3.22 (1.0) § 3.12 (1.28)
Costs (€):
Total cost 68448 (33374)* 52505 (26570) § 70337 (31975) 102581 (26963) §
Direct medical cost 34210 (3818)* 33062 (3793) § 34571 (3972) 36123 (2893) §
Direct non medical cost 10521 (8297)* 5525 (4651) § ¶ 11885 (7289) ¶ 19290 (9686) §
Informal care 2902 (2689)* 1594 (1637) § 3271 (2285) 5181 (3981) §
Indirect cost 23725 (25871) 13918 (20907) § 23879 (27042) 47167 (20799) §
Mean (Standard deviation).
*Significant difference between groups (one-factor ANOVA on ranks), p ≤ 0.05.
§, ¶ Significant difference between two groups (Bonferroni post-hoc test), p ≤ 0.05.
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French population [20], where 0 is equivalent to death and
1 is a good health. The second part is a Visual Analogue
Scale to measure self-perceived health with values from 0
to 100 (data not shown).MS specific QOL questionnaire
SEP-59 questionnaire is the validated French version [21]
of MSQOL-54, an international-used MS specific QOL
questionnaire [22], which combines the MOS SF36 to-
gether with MS specific items. It contains 59 items divided
in 15 domains named: physical function, role limitation –
physical, role limitation – emotional, social function, pain,
energy/fatigue, emotional well-being, health perception,
health distress, cognitive function, sexual function, sexual
satisfaction, overall QOL, sleep and social support. Scores
for each domain range from 0 to 100; higher scores indi-
cate better health status, except for the pain subscale. The
MSQOL-54 questionnaire, scored according to the User’
Manual, permits to produce two aggregated scores whichare a physical health QOL score (MSQOL-P) and a mental
health QOL score (MSQOL-M).
Medico-economic, demographic and clinical data
The investigators completed a detailed questionnaire for
each patient. This included questions on socio demo-
graphic characteristics, health status (type of MS, disease
duration, relapse rate in the last year), clinical examination
with EDSS measurement, concomitant health conditions,
questions to determine direct costs (medical drugs, out-
patient visits, hospitalizations related to MS, paraclinical
tests, laboratory tests, transportation - ambulances, multi-
disciplinary care, mobility aids and home furnishings, pro-
fessional care services at home and informal care, …) and
questions to determine indirect direct costs (employment
absenteeism, temporary or permanent reduction of work-
ing time or income, early retirement due to disability).
Procedure
The data were collected during face-to-face interviews of
45 to 60 minutes. First the patient responded alone to
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gator completed a medico-economic questionnaire with
the patient. Depending on the type of information, the
patient was asked about the period from the 3 to 12 last
months.
Data analysis
The data were analysed using SPSS version 18.0. De-
scriptive statistics are reported for the whole cohort and
split into 3 groups according to EDSS level. Definitions
of the 3 groups were decided before analysis. Ability to
walk without limits defined the first group (EDSS < 4).
Absence (EDSS between 4 and 5.5) or requirement of
assistance (EDSS ≥ 6) to walk a limited distance defined
the other two groups. Comparisons between groups were
analysed using the Conover free distribution (one-factor
ANOVA on ranks). When latter test showed significant
group differences, post-hoc tests were then performed. The
level of significance of comparisons was set at p = 0.05.
Concerning economic burden analysis, a societal per-
spective was adopted, in which all costs were considered
without regard to the entity that pays. Costs were calcu-
lated as mean annual costs per patient. For direct costs,
monetary values per unit were obtained from official
sources in French administration: hospital activity tariffs
(T2A), national health insurance tariffs and national price
list for drugs (www.ameli.fr). Indirect costs for lost prod-
uctivity were evaluated by a method named “human cap-
ital approach”, where the production of a person is valued
at the market price (in this case, the sex-specific average
salary including employers’ costs) using national labour
statistics (www.insee.fr). For short-term sick leave, labour
costs were adjusted to patients’ working hours, whereas
for long-term sick leave and early retirement due to MS,
the national average annual working time by sex was
used. Informal care was estimated by the replacement
method, where the care would be provided by a profes-
sional (driver, housekeeper, babysitter…) rather than a
family member.
Correlations were explored with Spearman coefficient(r)
and were considered significant with an alpha level of 0.01.
Post-hoc analysis on employment status included com-
parisons with Wilcoxon-Mann–Whitney test between par-
ticipants who have a job and those who had not.
Level of evidence
The report provides Class IV evidence and is a single
observational study without controls.
Results
Among 70 eligible patients with diagnosis of MS and
treatment by natalizumab in our centre, because of time-
consuming interviews and a limited time available in this
preliminary study, 42 were consecutively solicited. Allpatients being asked to participate accepted it, except
one. Demographic and disease characteristics are pre-
sented in Table 1. Sex-ratio Male/Woman was 7/34 and
mean age was 42.8 (SD 9.5) [23–72] years. Disease dur-
ation was 11.7 (SD 7.4) [2–40] years. EDSS score was
4.0 (SD 1.6) [1.5-7.0]. Demographic characteristics (age,
sex, disease duration and EDSS) were not significantly
different between participants and patients followed in
our centre and treated with natalizumab, who were not in-
cluded. Significant differences between groups for demo-
graphic and clinical data, utility, social participation and
economic costs are reported in Table 1. For MS-specific
QOL, only aggregated scores MSQOL-P and MSQOL-M
are presented.
Social participation and autonomy
Scores of the five dimensions of IPA were notably in-
creased, with higher scores expressing greater participation
reduction (Figure 1). Some domains of IPA questionnaire
were moderately correlated with EDSS, MSQOL-P and
MSQOL-M, and moderately to strongly with EQ5D-VAS
(Table 2).
MS specific QOL (SEP-59)
Mean scores of each SEP-59 domain are presented in
Figure 2. Physical aggregated score MSQOL-P was signifi-
cantly correlated with annual relapse rate (r = −0.435),
EQ5D-VAS (r = −0.678) and IPA questionnaire’s domains
(r = −0.403 to −0.595), but not with EDSS. Mental health
aggregated score, MSQOL-M, was only correlated with
family role (r = −0,501), autonomy outdoors (r = −0.640)
and EQ5D-VAS (r = 0.635) (Table 2). Numerous SEP-59
domains were correlated with IPA subscales (data not
shown). Significant correlations were found between the
number of relapses during the last year and physical
activities (r = −0.405), energy/fatigue (r = −0.49), pain
(r = −0.415) and cognitive functions (r = −0.473). Only sex-
ual function (r = −0.438), sexual satisfaction (r = −0.424)
and overall QOL (r = −0.434) were correlated to EDSS.
Burden of illness
The annual global cost per patient with MS was EUR
68448 (SD: EUR33374) (Table 1). The largest component
was the direct costs (65%). The cost attributed directly to
treatment by natalizumab (the price of drug itself, one day
hospitalization for administration and regular MRI survey)
was estimated to EUR 30256 (44%). The annual cost ex-
cluding natalizumab was EUR38622 (SD: EUR33374). Dir-
ect non-medical cost and informal care were respectively
15.4% and 4% of total costs. Indirect costs representing
lost productivity were also a substantial component (35%).
Only 39% of pwMS had a full time employment. The
proportion of early retirement due to MS was 40%. Mean
Figure 1 Mean scores for each IPA domain, in the entire population and 3 groups separated by EDSS. Scores for each domain range
from 0 to 4; lower scores indicate better social participation.
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utilities according to disease severity.
Total costs were correlated with four domains of the IPA
questionnaire: autonomy in doors (r = 0.519, p = 0.001),
family role (r = 0.583, p < 0.001), autonomy outdoors (r =
0.616, p < 0.001), work and education (r = 0.671, p < 0.001).
Concerning domains of SEP-59, total costs are correlated to
energy/fatigue (r = −0.481, p = 0.001), emotional well-being
(r = −0.399, p = 0.01), pain (r = 0.421, p = 0.006), health per-
ception (r = −0.419, p = 0.006), health distress (r = −0.452,
p = 0.003), overall QOL (r = −0.427, p = 0.005). Total costs
are also correlated with EDSS (r = 0.628, p < 0.001) and
EQ5D-VAS (r = −0.512, p = 0.001). Informal care was
correlated with autonomy in doors, family role, auton-
omy outdoors, work and education domains of IPA ques-
tionnaire (r = 0.51 to 0.59), cognitive function in SEP-59
(r = −0.413, p = 0.007), EDSS (r = 0.447, p = 0.003) and
EQ5D-VAS (r = −0.513, p = 0.001). Productivity losses were
only correlated with working and education domain of IPA
questionnaire (r = 0.544, p = 0.01). Utility (EQ5D-VAS) is
moderately to strongly correlated with the five domains of
IPA, and moderately with EDSS and SEP-59 (Table 2).Table 2 Correlations (r values) of quantitative instruments (Sp
EDSS E
IPA - Autonomy indoors 0.530** −
IPA - Family role 0.622** −
IPA - Autonomy outdoors 0.653** −
IPA - Social life 0.460* −





**p < 0.001; *p < 0.01.Employment status
Post-hoc analysis showed that patients, who were still
employed, had lower EDSS score (p < 0.001) and higher
education level (p = 0.02) in comparison to patients with-
out working activity. Social participation was equally bet-
ter when employment was maintained for the following
domains of IPA: family role (p = 0.02), autonomy outdoors
(p < 0.01), social life (p = 0.01) and work and education
(p < 0.001). QOL measured with EQ-5D (p < 0.01), MSQ
OL-P (p < 0.01) and MSQOL-M (p < 0.01) was also bet-
ter in this condition. Finally, global cost and these com-
ponents were all significantly lower if employment was
maintained.
Discussion
This study confirms that medico-economic costs due to
MS increase with impairment measured by EDSS. Social
participation evaluated by IPA questionnaire is altered in
patients with MS. We found significant correlations be-
tween IPA and QOL (EQ5D-VAS or SEP-59). Associ-
ation between QOL and EDSS was smaller (EQ5D-VAS)











Figure 2 Mean scores for each SEP-59 domain, in the entire population and 3 groups separated by EDSS. Scores for each domain range
from 0 to 100; higher scores indicate better health status, except for the pain subscale.
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variations of QOL. Other while, moderate to strong cor-
relations are evidenced between functional impairment
(EDSS), social participation and economic costs.
Patients’ perception of social participation in our study
was comparable with the results described in UK valid-
ation study of IPA [18]. The biggest change of IPA scores
was present between the 2 groups with EDSS range of
0–3.5 and 4.0-5.5 for the following domains of IPA: au-
tonomy indoors, family role, autonomy outdoors and
work and education. The known shift of utility, which
occurs when patients live a transition of EDSS score in
the range of 1.0-3.0 to 3.5-5.5 [14,23], seems to be simi-
lar for these domains of IPA. Groups’ stratification was
based on ability to walk. So walking impairment could
explain a part of this shift. Outcomes, as EDSS, EQ-5D
and probably IPA and MSQOL-P, are all sensitive to
walking impairment. In an other hand, IPA domain on
social life and relationships was significantly altered for
the group of patients with EDSS ≥ 6 in comparison with
patients which had unlimited walking ability. Stability of
the majority of IPA domains between the two groups
with higher EDSS scores is questionable and interesting.
We can hypothesize with cautious that a part of the in-
creasing economic costs with EDSS worsening can be
justify by the relative preservation of social participa-
tion. Social support and informal care could help pa-
tient to maintain some activities and a relative social
participation level. On the other hand, coping mecha-
nisms can influence the individuals’ perception of their
own quality or life and social participation. Acceptance
of disease could participate to limit worsening of QOL
or perception of participation, when disability due to
MS has progressed. But a larger study is necessary to
conclude on these hypotheses.
Correlations between IPA and QOL are found in this
study, in particular with generic utility (EQ-5D). An otherpreliminary study previously showed similar associa-
tions between specific activities like physical and leisure/
recreation activities and QOL in patients with MS [24].
However some domains of IPA are not or less correlated
to P- and M-MSQOL. But others factors as depression, fa-
tigue, pain, social support, living area, religiosity, which
are not lightened by our data, would probably contribute
to variations of MSQOL-M [25]. In this context, IPA do-
main on social life and relationships was expected to be
more correlated to MSQOL-M, but it was not verified in
our study. Kierkegaard and colleagues recently observed
that some manual dexterity, cognition and walking tests
could be used as predictive factors of participation limita-
tions [4]. Previous researches with the NARCOMS regis-
try have incriminated the earliest mobility impairment in
indirect costs’ increasing, activities of daily living, socio-
economic status and utility’s declining [26,27]. Indirect
costs (mostly productivity losses) driven by working ability
and early retirement are often considered as the most im-
portant factor to explain global cost increasing with MS
progression [10,28]. In this study, the post-hoc analysis
confirmed that ability to maintain employment is an im-
portant outcome and could be considered as a good
marker of well-being. Economically, patients who have a
job still contribute to the Gross Domestic Product of
their country. So, direct costs due to MS are at least
partly neutralized by their economic contribution.
The mean overall cost of MS seems increased in com-
parison of previous studies. This observation is explained
mostly by the high cost of natalizumab. Noteworthy, this
study did not aim to evaluate a cost/benefit ratio for this
treatment. The calculated global burden is similar in pro-
portion to previous French and international data [6,10,29],
usually collected by postal questionnaires and therefore
weakened by inherent biases. In France, Kobelt and col-
leagues conducted the larger costs’ evaluation in 2007.
Excluding disease-modifying drugs’ cost, estimated global
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sults (38622 +/− 33374 EUR). Utility values (EQ5D-VAS)
are also very similar with a mean value to 0.52 (SD 0.29) in
2007 compared to 0.52 (SD 0.28) in this study [29].
International Conference on Disability Outcomes in
MS on May 2011 underlines how wider assessments of
function are potentially useful and could be acceptable
by regulators [2]. Global measures of disability should be
used as adjunct to or replace MS-specific outcomes de-
pend on the purpose of the study. Regulation agencies
such as FDA in USA, NICE in UK or HAS in France
recommend evaluating utility by generic measures of QOL
related to health status in economic analysis of health cares
(such as EQ5D-VAS, SF-6D or HUI-III). These generic
tools allow comparison of a disease to another to facilitate
decision-making, but these do not capture several import-
ant areas for pwMS. This may lead to an underestimation
of the impact of disability in patients [30]. In “cost-utility”
or “cost of illness” studies, utility which is mostly expressed
like Quality-adjusted life years (QALYs), is used as a
comparator outcome to economic costs driven by clin-
ical factors like relapse rates and disease progression.
QALYs measures both quantity (mortality) and quality
(morbidity) of life. It reflects the relative desirability or
value of the health states that are described by changes
in lifestyle of patient including pain, anxiety, social func-
tioning and ability to continue activities of daily living
(including leisure). In the conventional approach, ratio
between global economic costs and QALY (Costs/QALY)
needs to be as small as possible and first objective of a
healthcare action is to maximize utility. However using
QALY method is still very controversial, particularly in
population concerned with disability [31]. According to
theory developed by Amartya Sen and others [32,33],
the level of wellbeing of a person with disabilities is less
affected by changes in health status than the effect of
these changes on its functionings and ultimately on their
social participation [34]. Tools that explore social partici-
pation and quality of life share some common elements
[35]. In the definition of QOL by the World Health
Organisation, QOL can be seen as consequence of the
bio-psycho-social model defined in the International
Classification of Functioning, Disability and Health (ICF).
So the level of social participation could influence quality
of life, but it does not exactly measure the same concept.
In accordance with our results, we propose that social par-
ticipation measure is a complementary outcome, which
highlights different concepts than QOL level.
Limitations
Several limitations have to be reported in our study. The
small size of patients’ sample decreases the strength of
associations between the different elements studied and
limits the generality of ours results. However, significantcorrelations were reported only when alpha risk was less
than or equal to 0.01. On the other hand, economic costs
and observed utility values are very close to those found
in previous studies. Functional assessment of patients,
more precisely than does EDSS, with evaluation of walk-
ing, vision, balance, cognitive functions, as well as fatigue
and depression could enable better understanding of pre-
dicting factor for impaired social participation. Finally,
IPA questionnaire seems to us to be a promising tool still
little used today to measure social participation and dis-
ability. Numerous tools evaluating specifically functional
independence and social participation are available [35],
but multiplicity of tools and often time-consuming ques-
tionnaires limit their use. Only four scales are validated in
French (SMAF, LIFE-H, WHODAS-II and IPA). Among
these scales, only two of them, Impact on Participation
and Autonomy Questionnaire (IPA) [18] and WHODAS-
II [36], have been validated for MS. All questions in IPA
are related to activities or participation as defined in ICF.
By contrast, some items of WHODAS II are not related to
these concepts of activities or social participation [35,37].
So authors chose IPA to limit confusion in interpretation
of the results. Finally a consensus is needed to achieve
common disability outcomes.
Conclusion
From a small sample of pwMS, links between progression
of the disease (EDSS), generic QOL, social participation
and economic costs seem obvious and consistent with
previous national economic data. Moderate to strong cor-
relations of social participation with health status (EDSS),
QOL, utility and economic costs encourage exploring bet-
ter these links in larger cohort.
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